Agenda Item # 3
ICOC/Application
Subcommittee Meeting
October 19, 2016



Translating Center GWG Review and Recommendations

Gil Sambrano

Director, Portfolio Development and Review

CIRM Infrastructure Programs

Program	Goal	Role		
Translating Center	Shorten time to clinical testing	Process DevelopmentIND-enabling activities		
Accelerating Center	Accelerate clinical research	Regulatory SubmissionsTrial management		
Alpha Clinics Network	Conduct high quality clinical trials	 Specialize in cell therapy clinical trials Develop AVARs (Accelerating and Value Add Resources) 		



Translating Center



- CIRM funding for a Stem Cell focused Preclinical Research Organization
- Operating within California
- Up to \$15 million over five years



Translating Center Core Services

- Consultation Services
- Project Management
- Preclinical Development Research
- Process Development
- Product Manufacturing
- Regulatory Filing Support

Services will be proportional to the needs of the projects



Sustainability

- Through acquisition of unique insight and experience by supporting CIRM's projects, the TC will be positioned to develop specialized approaches and services for cell therapy trials
- The TC is expected to leverage these assets to create a sustainable platform for support of cell therapy development and stem cell clinical trials



GWG Review Criteria

- Does the proposed center hold the necessary significance and potential for impact?
- Has the applicant developed a plan designed to successfully establish and operationalize the center?
- Is the proposal feasible?



"Pitch"

 Applicant teams were invited to give a 15 minute presentation before the GWG to address vision, value proposition, and sustainability.

 GWG had opportunity to ask questions directly of the team members.



Scoring System

Score of "85-100"

Exceptional merit and warrants funding, if funds are available.

Only the application with the highest average score will be recommended for funding.

Score of "1-84"

Not recommended for funding.

Applications are scored by all scientific members of the GWG with no conflict.

Final Vote (2 parts)

- All members: "The review was scientifically rigorous, there was sufficient time for all viewpoints to be heard, and the scores reflect the recommendation of the GWG."
- 2. Patient advocate members: "The review was carried out in a fair manner and was free from undue bias."

All members voted unanimously in favor of 1 (20-0)

Patient Advocate GWG members voted unanimously in favor of 2 (5-0)



INFR2: GWG Recommendations

	Apps	Funds
Score 85-100 Exceptional merit and warrant funding, if funds available	1	\$15M
Score 1-84 Not recommended for funding	3	



INFR2-09298

SCORE	Median	SD	High	Low
89	90	5	95	75

CIRM Team Recommendation: Fund (concur with GWG recommendation)

Award Amount: \$15M



INFR2-09233

SCORE	Median	SD	High	Low
<60				

CIRM Team Recommendation: Do not fund (concur with GWG recommendation)

